MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. has been in discussion over the previous eight months regarding the formation of a joint venture partnership. INNP has reached a point in these negotiations where final written terms have been submitted on all key issues which could lead to the Company’s very first product acquisition. It should be noted that this process evolved methodically over this extended period due to the successful, long term history of the product involved, and the well-established reputation of its founding corporation.
Management anticipates additional forthcoming news and progress updates on the closing of this transaction that can complete great strides in two specific areas. One is the awarding of valuable rights to Innolife Pharma of an industry leading product. This established brand known for innovation and consistency over more than two decades can be launched in a brand new target market for the first time representing the largest market of this type on a global scale. Secondly, but of equal importance, is the solidifying of a joint venture with a partner of great quality and experience. The intention is to unite the market access and distribution capabilities of INNP with the knowledge, leadership, and existing contacts of our potential joint venture partner.
INNP will continue to reveal details of our aggressive strategy geared towards long term growth as they become available. We are confident that a partnership will emerge and start to bring in revenue in the near term based on the high level of negotiations reached with an industry leader in the information technology field. The Company believes that the size of our target market is potentially in excess of US$20 Billion. Updates will also be available on the Company’s official corporate web site at www.innolifepharma.com. Please bear with us as the site is still under development, but will be officially launched upon finalization of our partnership and product acquisition.
FORWARD-LOOKING STATEMENTS:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.
CONTACT: Innolife Pharma, Inc., (905) 943-4938, Email:
info@innolifepharma.com
